Trials / Completed
CompletedNCT01596400
Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years
An Open-label, Cross-over, Pharmacokinetic Study to Assess the Safety and Pharmacokinetics of Transdermal Granisetron (Sancuso® Patch) and IV Granisetron in a Pediatric Oncology Population (Aged 13 to 17 Years)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd · Industry
- Sex
- All
- Age
- 13 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the dosing strategy for adolescents aged 13 to 17 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | granisetron transdermal system | patch |
| DRUG | Granisetron IV | IV |
Timeline
- Start date
- 2012-05-01
- Primary completion
- 2015-08-01
- Completion
- 2016-12-01
- First posted
- 2012-05-11
- Last updated
- 2024-06-17
Locations
12 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01596400. Inclusion in this directory is not an endorsement.